Unique ID issued by UMIN | UMIN000030184 |
---|---|
Receipt number | R000034461 |
Scientific Title | Effects of continuous ingestion of partially hydrolyzed guar gum on soft stool by intestinal bacterial flora |
Date of disclosure of the study information | 2018/12/01 |
Last modified on | 2020/06/14 08:55:41 |
Effects of continuous ingestion of partially hydrolyzed guar gum on soft stool by intestinal bacterial flora
Effects of partially hydrolyzed guar gum on soft stool
Effects of continuous ingestion of partially hydrolyzed guar gum on soft stool by intestinal bacterial flora
Effects of partially hydrolyzed guar gum on soft stool
Japan |
Healthy adult
Adult |
Others
NO
Investigation of effects of food containing partially hydrolyzed guar gum on stool character and intestinal bacterial flora
Efficacy
Bowel Survey
Intestinal bacterial Flora, blood metabolite, questionnaire
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
Oral intake of the food containing partially hydrolyzed guar gum (continuous)
Oral intake of placebo food (continuo
us)
20 | years-old | <= |
49 | years-old | >= |
Male and Female
1. Japanese male and female volunteers
(20 to 49 years).
2. Healthy people.
3. Who has trends of diahhrea.
4. Who can give informed consent by the document based on the individual's intention before the start of the study.
5. Who can visit the clinic during the test period.
People who meet any of the following conditions will be excluded.
1. Who is likely to be inflammatory bowel disease, gastrointestinal ulcers, pancreatitis, celiac disease, lactose intolerance, protozoan infection, parasitic infection, other organic gastrointestinal disease or pregnant women.
2. Who uses commercially available drug or a quasi-drugs, for the prevention and treatment of diarrhea with abdominal pain and abdominal discomfort, on a daily basis.
3. Who is currently going to hospital for the treatment of diarrhea with abdominal pain and abdominal discomfort.
4. Who is judged by principal investigator to require medical treatment because of severe diarrhea with abdominal pain and abdominal discomfort.
5. Who has been diagnosed with irritable bowel syndrome.
6. Who has experienced a gastrointestinal surgery, excluding operation for appendicitis.
7. Who is in breast-feeding or pregnancy, or wishes to become pregnant during the study period.
8. Who has been treated for some systemic disease.
9. Who uses non-steroidal anti-inflammatory drugs, steroids or antibiotics on a daily basis.
10. Who is smoker -excluding who have quitted smoking for one year or more.
11. Who has an abnormality in the blood test excluding who is judged by principal investigator as in range of physiological variation.
12. Who had participated in a clinical trial within 60 days before a screening test.
13. Who is irresponsible-mental illness, dementia etc.
14. Who is sufferring or have sufferred allergic reaction to food or drug.
15. Who is judged as ineligible by principal investigators or researchers.
40
1st name | Sachiyo |
Middle name | |
Last name | Sakaguchi |
Medical Corporation K. Medical Office
TOC Building Clinic
141-0031
7-22-17 Nishigotanda Shinagawa-ku Tokyo
03-3494-2491
kenshin@kmo.or.jp
1st name | Zenta |
Middle name | |
Last name | Yasukawa |
Taiyo Kagaku Co., Ltd.
Nutrition division
510-0844
1-3, Takara-cho, Yokkaichi-shi, Mie,
059-347-5411
zyasukawa@taiyokagaku.co.jp
imeQ Co.Ltd.
Taiyo Kagaku Co., Ltd.
Profit organization
Kyoto Prefectural University of Medicine
SUDA Clinic Institutional Review Board
2-8-14 Takadanobaba, Shinjuku-ku, Tokyo
03-6205-6222
m-yamada@imeq.co.jp
NO
医療法人社団ケイメディカルオフィス(東京都)
2018 | Year | 12 | Month | 01 | Day |
None
Published
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769658/
44
Intake of the PHGG for 3 months significantly improved stool form, evaluated using BSS, and had no effects on stool frequency. BSS was significantly normalized in the group consuming the PHGG compared with the placebo. Comprehensive fecal microbiome analysis by the 16S rRNA-sequence method detected significant changes in the ratio of some bacteria, such as an increase of Bifidobacterium (p < 0.05) in the PHGG group.
2020 | Year | 06 | Month | 14 | Day |
subjects who were healthy with a loose stool
Forty-four volunteers were selected as study subjects from eighty-eight healthy Japanese male and female.
None.
Fecal characteristics, fecal frequency, serum bile acids, QoL etc
Completed
2017 | Year | 11 | Month | 27 | Day |
2017 | Year | 11 | Month | 28 | Day |
2017 | Year | 12 | Month | 18 | Day |
2018 | Year | 06 | Month | 30 | Day |
Nutrients. 2019 Sep; 11(9): 2170.
doi: 10.3390/nu11092170
2017 | Year | 11 | Month | 30 | Day |
2020 | Year | 06 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034461
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |